FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lenalidomide product as …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome with 5q Deletion
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

SUPPL AP for LENALIDOMIDE (LENALIDOMIDE)